Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect

Lung Cancer

Volumn 73, Issue 2, 2011, Pages 158-165

  Spiliotaki, Maria ^a   Markomanolaki, Haris ^a   Mela, Marilena ^a   Mavroudis, Dimitris ^a,b   Georgoulias, Vassilis ^a,b   Agelaki, Sofia ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anti tumor; IGF IR; NSCLC; Paclitaxel; Proliferation; VEGF

Indexed keywords

AVE 1642; PACLITAXEL; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; DRUG INTERACTIONS; ENDOTHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960064810     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.11.010     Document Type: Article

References (38)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-108.
2. Reck M., Crino L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009, 63:1-9.
3. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995, 16:143-163.
4. Dufourny B., Alblas J., van Teeffelen H.A., van Schaik F.M., van der B.B., Steenbergh P.H., et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997, 272:31163-31171.
5. Jackson J.G., White M.F., Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem 1998, 273:9994-10003.
6. Kulik G., Klippel A., Weber M.J. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997, 17:1595-1606.
7. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
8. Casa A.J., Dearth R.K., Litzenburger B.C., Lee A.V., Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008, 13:3273-3287.
9. Bohula E.A., Playford M.P., Macaulay V.M. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003, 14:669-682.
10. Beppu K., Nakamura K., Linehan W.M., Rapisarda A., Thiele C.J. Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 2005, 65:4775-4781.
11. Bermont L., Lamielle F., Fauconnet S., Esumi H., Weisz A., Adessi G.L. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells. Int J Cancer 2000, 85:117-123.
12. Goad D.L., Rubin J., Wang H., Tashjian A.H., Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 1996, 137:2262-2268.
13. Slomiany M.G., Rosenzweig S.A. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J Pharmacol Exp Ther 2006, 318:666-675.
14. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996, 271:29483-29488.
15. Frankel S.K., Cosgrove G.P., Cha S.I., Cool C.D., Wynes M.W., Edelman B.L., et al. TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis. Am J Respir Cell Mol Biol 2006, 34:293-304.
16. Chang Y.S., Kong G., Sun S., Liu D., El-Naggar A.K., Khuri F.R., et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3796-3802.
17. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999, 91:151-156.
18. Morgillo F., Woo J.K., Kim E.S., Hong W.K., Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66:10100-10111.
19. Maloney E.K., McLaughlin J.L., Dagdigian N.E., Garrett L.M., Connors K.M., Zhou X.M., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003, 63:5073-5083.
20. Dziadziuszko R., Camidge D.R., Hirsch F.R. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008, 3:815-818.
21. Favoni R.E., de C.A., Ravera F., Cantoni C., Pirani P., Ardizzoni A., et al. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 1994, 56:858-866.
22. Gross J.M., Yee D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Rev 2003, 22:327-336.
23. Nakanishi Y., Mulshine J.L., Kasprzyk P.G., Natale R.B., Maneckjee R., Avis I., et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988, 82:354-359.
24. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5:221-230.
25. Descamps G., Wuilleme-Toumi S., Trichet V., Venot C., Debussche L., Hercend T., et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006, 177:4218-4223.
26. Zeng X., Sachdev D., Zhang H., Gaillard-Kelly M., Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res 2009, 15:2840-2849.
27. LeRoith D., Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004, 5:201-202.
28. Dunn S.E., Hardman R.A., Kari F.W., Barrett J.C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997, 57:2687-2693.
29. Gooch J.L., Van Den Berg C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999, 56:1-10.
30. Beech D.J., Parekh N., Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001, 8:325-329.
31. Dunn S.E., Ehrlich M., Sharp N.J., Reiss K., Solomon G., Hawkins R., et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998, 58:3353-3361.
32. Hellawell G.O., Ferguson D.J., Brewster S.F., Macaulay V.M. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 2003, 91:271-277.
33. Warshamana-Greene G.S., Litz J., Buchdunger E., Garcia-Echeverria C., Hofmann F., Krystal G.W. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005, 11:1563-1571.
34. Wu J.D., Odman A., Higgins L.M., Haugk K., Vessella R., Ludwig D.L., et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005, 11:3065-3074.
35. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
36. Reinmuth N., Liu W., Fan F., Jung Y.D., Ahmad S.A., Stoeltzing O., et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002, 8:3259-3269.
37. Wu K.D., Zhou L., Burtrum D., Ludwig D.L., Moore M.A. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007, 56:343-357.
38. Long L., Rubin R., Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 1998, 238:116-121.